A Whole-Genome CRISPR Screen IdentifiesAHRLoss as a Mechanism of Resistance to a PARP7 Inhibitor

Huadong Chen, Morgan E. Diolaiti, Patrick C. O'Leary, Ajda Rojc, Nevan J. Krogan, Minkyu Kim, Alan Ashworth

Producción científica: Articlerevisión exhaustiva

7 Citas (Scopus)

Resumen

Inhibitors directed toward PARP1 and PARP2 are approved agents for the treatment of BRCA1 and BRCA2-related cancers. Other members of the PARP family have also been implicated in cancer and are being assessed as therapeutic targets in cancer and other diseases. Recently, an inhibitor of PARP7 (RBN-2397) has reached early-stage human clinical trials. Here, we performed a genome-wide CRISPR screen for genes that modify the response of cells to RBN-2397. We identify the polycyclic aromatic hydrocarbon receptor AHR and multiple components of the cohesin complex as determinants of resistance to this agent. Activators and inhibitors of AHR modulate the cellular response to PARP7 inhibition, suggesting potential combination therapy approaches.

Idioma originalEnglish (US)
Páginas (desde-hasta)1076-1089
Número de páginas14
PublicaciónMolecular cancer therapeutics
Volumen21
N.º7
DOI
EstadoPublished - jul 2022
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'A Whole-Genome CRISPR Screen IdentifiesAHRLoss as a Mechanism of Resistance to a PARP7 Inhibitor'. En conjunto forman una huella única.

Citar esto